A 56-year-old man has had right-upper-quadrant abdominal pain for several months but is otherwise healthy. He does not drink alcohol, has not been exposed to other hepatotoxins, and takes no medications. On physical examination, vital signs are normal. Abdominal examination reveals hepatosplenomegaly. The remainder of the physical exam is normal. What would you do?

A new cohort study has found physical, mental, and cognitive symptoms in patients one year after being treated in an intensive care unit (ICU) for COVID-19. The study involved an exploratory multicenter prospective cohort study that included 246 patients who were alive one year following ICU treatment for COVID-19. Three-quarters of patients reported physical symptoms, 1/4 reported mental symptoms, and about 15% reported cognitive symptoms a year after being hospitalized with the respiratory illness.

A proposed six-step approach to making sense of arterial blood gas (ABG) labs. This six-step process with simple table support helps ensure a complete and understandable interpretation of every ABG.

Dana Farber’s CLL Center associate director Matthew S. Davids, MD, MMSc highlights some of his key takeaways from the recent ASH meeting: Novel treatment approaches in chronic lymphocytic leukemia (CLL), including large phase 3 studies, some smaller studies combining novel drugs, and long-term follow-ups of prior phase 3 studies; three reports with practice-changing implications; and a surprising finding in the ECOG 1912 study, which demonstrated an overall survival benefit for patients who received ibrutinib with rituximab.

This study reports long term outcomes on CALGB 40603 at a median follow-up of 7.9 years. Event-free survival and other LTOs were not significantly improved with either study drug overall or in studied sub-populations. Results showed that patients with any residual disease had significantly worse outcomes. This finding supports considering adjuvant therapy even in the setting of minimal residual disease.

This update of the GO29365 study shows significant survival benefit with pola + BR vs BR alone in R/R, transplant ineligible DLBCL. In the randomization arms, median progression-free survival was 9.2 vs 3.7 months and median overall survival was 12.4 vs 4.7 months for the pola + BR arm vs the BR arm. In the extension cohort, the OR rate was 41.5%, and the CR rate was 38.7%; PFS and OS were 6.6 months and 12.5 months, respectively.